LONDON, UK and NEW YORK, NY, USA I July 16, 2025 I OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, ...

New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the ...

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

GUANGZHOU, China I July 16, 2025 I Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

NEW YORK, NY, USA I July 15, 2025 I SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...

GL-IL2-138 is a small molecule RNA agent that modulates natural IL-2, allowing for downregulating or upregulating the immune system to fight devastating ...

LOS ANGELES, CA, USA I July 15 2025 I Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer ...

I Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...

Chemspace/Enamine positioned to augment product and service offerings – Orogen to gain potential novel therapeutic s ...